Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. More Details
Adequate balance sheet with limited growth.
Share Price & News
How has Cerus's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CERS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: CERS's weekly volatility (6%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: CERS exceeded the US Medical Equipment industry which returned 20.5% over the past year.
Return vs Market: CERS exceeded the US Market which returned 19.1% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Cerus's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall StIs Cerus (NASDAQ:CERS) A Risky Investment?
1 month ago | Simply Wall StInvestors Who Bought Cerus (NASDAQ:CERS) Shares Three Years Ago Are Now Up 124%
1 month ago | Simply Wall StCould The Cerus Corporation (NASDAQ:CERS) Ownership Structure Tell Us Something Useful?
Is Cerus undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CERS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CERS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CERS is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: CERS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CERS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CERS is overvalued based on its PB Ratio (9.5x) compared to the US Medical Equipment industry average (4.4x).
How is Cerus forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CERS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CERS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CERS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CERS's revenue (22.2% per year) is forecast to grow faster than the US market (10.2% per year).
High Growth Revenue: CERS's revenue (22.2% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CERS's Return on Equity is forecast to be high in 3 years time
How has Cerus performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CERS is currently unprofitable.
Growing Profit Margin: CERS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CERS is unprofitable, and losses have increased over the past 5 years at a rate of 1.6% per year.
Accelerating Growth: Unable to compare CERS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CERS is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.6%).
Return on Equity
High ROE: CERS has a negative Return on Equity (-57.12%), as it is currently unprofitable.
How is Cerus's financial position?
Financial Position Analysis
Short Term Liabilities: CERS's short term assets ($177.3M) exceed its short term liabilities ($46.2M).
Long Term Liabilities: CERS's short term assets ($177.3M) exceed its long term liabilities ($57.9M).
Debt to Equity History and Analysis
Debt Level: CERS's debt to equity ratio (40.8%) is considered high.
Reducing Debt: CERS's debt to equity ratio has increased from 20.8% to 40.8% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CERS has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: CERS has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 3.9% each year.
What is Cerus's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CERS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CERS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CERS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CERS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CERS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Obi Greenman (53 yo)
Mr. William M. Greenman, also known as Obi, has been the Chief Executive Officer and President of Cerus Corporation since April 2011. Mr. Greenman served as the Chief Business Officer of Cerus Corporation ...
CEO Compensation Analysis
Compensation vs Market: Obi's total compensation ($USD3.27M) is about average for companies of similar size in the US market ($USD2.60M).
Compensation vs Earnings: Obi's compensation has increased whilst the company is unprofitable.
|Co-Founder & Chief Scientific Officer||no data||US$1.29m||1.14% |
|VP of Finance & CFO||7.75yrs||US$1.25m||0.060% |
|Chief Operating Officer||0.67yr||US$1.31m||0.096% |
|Chief Medical Officer||5.33yrs||US$1.26m||0.025% |
|VP of Administration & Corporate Secretary||21.83yrs||no data||no data|
|Investor Relations Director||no data||no data||no data|
|Chief Legal Officer & General Counsel||7.92yrs||US$804.35k||0.029% |
|Vice President of Global Marketing||no data||no data||no data|
|Senior Vice President of Regulatory Affairs||7.75yrs||US$847.11k||0.072% |
|VP of Development & Red Blood Cell Program Leader||8.83yrs||no data||no data|
Experienced Management: CERS's management team is seasoned and experienced (7.8 years average tenure).
|Independent Director||17.5yrs||US$170.43k||0.13% |
|Independent Director||6.67yrs||US$168.43k||0.043% |
|Independent Director||2.08yrs||US$66.00k||0.017% |
|Independent Chairman||7.08yrs||US$210.58k||0.036% |
|Independent Director||1.67yrs||US$227.26k||0.0045% |
|Independent Director||13.08yrs||US$168.43k||0.028% |
|Independent Director||2.17yrs||US$48.00k||0.0073% |
Experienced Board: CERS's board of directors are considered experienced (6.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.6%.
Cerus Corporation's company bio, employee growth, exchange listings and data sources
- Name: Cerus Corporation
- Ticker: CERS
- Exchange: NasdaqGM
- Founded: 1991
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$1.045b
- Shares outstanding: 167.14m
- Website: https://www.cerus.com
Number of Employees
- Cerus Corporation
- 1220 Concord Avenue
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|CERS||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Jan 1997|
|CU2||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 1997|
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for cont...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/24 00:24|
|End of Day Share Price||2020/11/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.